Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paramethadione. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paramethadione SCHEMBL317346 | 1.00 | LMNA (0.56) | LMNAATMPGRTSHRCYP2C19 | |
| Paramethadione SCHEMBL23832172 | 0.92 | LMNA (0.70) | LMNAPGRELANECTSGPRTN3 | |
| SCHEMBL1363134 | 0.81 | LMNA (0.54) | LMNA | |
| SCHEMBL8363739 | 0.76 | LMNA (0.52) | LMNAATMPGRTSHRCYP2C19 | |
| Trimethadione SCHEMBL28882 | 0.72 | LMNA (1.00) | LMNAPGRELANECTSGPRTN3 | |
| SCHEMBL13581345 | 0.70 | LMNA (0.42) | LMNAELANECTSGPRTN3 | |
| SCHEMBL13581344 | 0.70 | LMNA (0.42) | LMNAELANECTSGPRTN3 | |
| SCHEMBL1362309 | 0.68 | LMNA (0.60) | LMNA | |
| Ethadione SCHEMBL13724326 | 0.68 | LMNA (0.70) | LMNAPGRELANECTSGPRTN3 | |
| SCHEMBL887992 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4170 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| US-20240216409-A1 | Patient Treatment Via Teratogenic Pharmaceutical Compounds | NANT HOLDINGS IP, LLC (US) | 2024-07-04 | — | — | US | claimed |
| US-11786487-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-10-17 | — | — | US | claimed |
| US-20230301961-A1 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2023-09-28 | — | — | US | claimed |
| WO-2023178250-A1 | TREATMENT OF TUBEROUS SCLEROSIS WITH MIRDAMETINIB | SpringWorks Therapeutics Inc. (US) | 2023-09-21 | — | — | WO | claimed |
| US-11759440-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-09-19 | — | — | US | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-11690821-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2023-07-04 | — | — | US | claimed |
| US-20210393550-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-12-23 | — | — | US | claimed |
| US-5585243-A | SEPARATELY INCUBATING HUMAN PLATELETS WITH BLOOD SAMPLE ANDREAGENT DRUG SOLUTION TO FORM COMPLEXES, DETERMINING AMOUNT OF BOUND ANTIBODY | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1996-12-17 | — | — | US | claimed |
| EP-0746342-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD. (US) | 1996-12-11 | — | — | EP | claimed |
| US-5518730-A | Biodegradable controlled release flash flow melt-spun delivery system | FUISZ TECHNOLOGIES LTD. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0746342-A4 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD (US) | 1996-01-11 | — | — | EP | claimed |
| WO-1995029665-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1995-11-09 | — | — | WO | claimed |
| WO-1995008116-A1 | METHOD OF DETECTING CYTOPENIA THAT IS MEDIATED BY DRUG-DEPENDENT ANTIBODY BINDING TO BLOOD CELLS | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-4160818-A | Fluorimetric immunoassay for diphenylhydantoin | TECHNICON INSTRUMENTS CORPORATION (US) | 1979-07-10 | — | — | US | claimed |